Tags

Type your tag names separated by a space and hit enter

Nanoparticle formulation increases Syzygium cumini antioxidant activity in Candida albicans-infected diabetic rats.
Pharm Biol. 2017 Dec; 55(1):1082-1088.PB

Abstract

CONTEXT

Syzygium cumini (L.) Skeels (Myrtaceae) is a medicinal plant widely used in folk medicine for the treatment of diabetes mellitus (DM). However, studies on the use of this plant and of nanoparticle formulations against DM-related fungal infections are scarce.

OBJECTIVE

To evaluate the effect of the treatments with aqueous seed extract of S. cumini (ASc) and ASc-loaded polymeric nanoparticles (NPASc) on biochemical parameters in Candida albicans-infected diabetic rats.

MATERIALS AND METHODS

Male Wistar rats were divided into eight groups: Control, DM, C. albicans, C. albicans + ASc, C. albicans + NPASc, DM + C. albicans, DM + C. albicans + ASc and DM + C. albicans + NPASc. Rats were daily treated with ASc or NPASc (100 mg/kg) for 21 days. Biochemical parameters in serum and urine, advanced oxidation protein product (AOPP) and TBARS levels in the serum, kidney, liver and pancreas and N-acetyl-β-d-glucosaminidase (NAG) activities in kidney and urine were evaluated.

RESULTS

Biochemical and oxidative stress parameters increased in rats with DM and/or candidiasis. NPASc was more effective than ASc in decreasing glucose (56%), cholesterol (33%) and creatinine (51%) levels; serum (16%) and pancreatic (46%) AOPP and renal (48%) TBARS levels when compared with DM + C. albicans group. In C. albicans group, both treatments decreased NAG activity but did not decrease creatinine levels.

CONCLUSIONS

These data suggest that the use of nanotechnology is able to improve plant extract properties such as antioxidant activity that may be useful in diabetes-related complications.

Authors+Show Affiliations

a Departamento de Análises Clínicas e Toxicológicas , Centro de Ciências da Saúde, Programa de Pós-Graduação em Ciências Farmacêuticas, Universidade Federal de Santa Maria , Santa Maria , Brazil.a Departamento de Análises Clínicas e Toxicológicas , Centro de Ciências da Saúde, Programa de Pós-Graduação em Ciências Farmacêuticas, Universidade Federal de Santa Maria , Santa Maria , Brazil.a Departamento de Análises Clínicas e Toxicológicas , Centro de Ciências da Saúde, Programa de Pós-Graduação em Ciências Farmacêuticas, Universidade Federal de Santa Maria , Santa Maria , Brazil.a Departamento de Análises Clínicas e Toxicológicas , Centro de Ciências da Saúde, Programa de Pós-Graduação em Ciências Farmacêuticas, Universidade Federal de Santa Maria , Santa Maria , Brazil.b Departamento de Farmácia Industrial , Centro de Ciências da Saúde, Programa de Pós-Graduação em Ciências Farmacêuticas, Universidade Federal de Santa Maria , Santa Maria , Brazil.a Departamento de Análises Clínicas e Toxicológicas , Centro de Ciências da Saúde, Programa de Pós-Graduação em Ciências Farmacêuticas, Universidade Federal de Santa Maria , Santa Maria , Brazil.c Departamento de Microbiologia , Centro de Ciências da Saúde, Programa de Pós-Graduação em Ciências Farmacêuticas, Universidade Federal de Santa Maria , Santa Maria , Brazil.a Departamento de Análises Clínicas e Toxicológicas , Centro de Ciências da Saúde, Programa de Pós-Graduação em Ciências Farmacêuticas, Universidade Federal de Santa Maria , Santa Maria , Brazil.b Departamento de Farmácia Industrial , Centro de Ciências da Saúde, Programa de Pós-Graduação em Ciências Farmacêuticas, Universidade Federal de Santa Maria , Santa Maria , Brazil.a Departamento de Análises Clínicas e Toxicológicas , Centro de Ciências da Saúde, Programa de Pós-Graduação em Ciências Farmacêuticas, Universidade Federal de Santa Maria , Santa Maria , Brazil.b Departamento de Farmácia Industrial , Centro de Ciências da Saúde, Programa de Pós-Graduação em Ciências Farmacêuticas, Universidade Federal de Santa Maria , Santa Maria , Brazil.d Programa de Pós-Graduação em Ciências Biológicas: Farmacologia e Terapêutica , Universidade Federal do Rio Grande do Sul , Porto Alegre , Brazil.c Departamento de Microbiologia , Centro de Ciências da Saúde, Programa de Pós-Graduação em Ciências Farmacêuticas, Universidade Federal de Santa Maria , Santa Maria , Brazil.a Departamento de Análises Clínicas e Toxicológicas , Centro de Ciências da Saúde, Programa de Pós-Graduação em Ciências Farmacêuticas, Universidade Federal de Santa Maria , Santa Maria , Brazil.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

28193098

Citation

Bitencourt, Paula E R., et al. "Nanoparticle Formulation Increases Syzygium Cumini Antioxidant Activity in Candida Albicans-infected Diabetic Rats." Pharmaceutical Biology, vol. 55, no. 1, 2017, pp. 1082-1088.
Bitencourt PE, Cargnelutti LO, Stein CS, et al. Nanoparticle formulation increases Syzygium cumini antioxidant activity in Candida albicans-infected diabetic rats. Pharm Biol. 2017;55(1):1082-1088.
Bitencourt, P. E., Cargnelutti, L. O., Stein, C. S., Lautenchleger, R., Ferreira, L. M., Sangoi, M., Denardi, L., Borges, R. M., Boligon, A., Moresco, R. N., Cruz, L., Zanette, R. A., Alves, S. H., & Moretto, M. B. (2017). Nanoparticle formulation increases Syzygium cumini antioxidant activity in Candida albicans-infected diabetic rats. Pharmaceutical Biology, 55(1), 1082-1088. https://doi.org/10.1080/13880209.2017.1283338
Bitencourt PE, et al. Nanoparticle Formulation Increases Syzygium Cumini Antioxidant Activity in Candida Albicans-infected Diabetic Rats. Pharm Biol. 2017;55(1):1082-1088. PubMed PMID: 28193098.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Nanoparticle formulation increases Syzygium cumini antioxidant activity in Candida albicans-infected diabetic rats. AU - Bitencourt,Paula E R, AU - Cargnelutti,Lariane O, AU - Stein,Carolina S, AU - Lautenchleger,Raquel, AU - Ferreira,Luana M, AU - Sangoi,Manuela, AU - Denardi,Laura, AU - Borges,Raphaela M, AU - Boligon,Aline, AU - Moresco,Rafael N, AU - Cruz,Letícia, AU - Zanette,Régis A, AU - Alves,Sydney H, AU - Moretto,Maria Beatriz, PY - 2017/2/15/entrez PY - 2017/2/15/pubmed PY - 2017/3/10/medline KW - Advanced oxidation protein product KW - N-acetyl-β-d-glucosaminidase KW - TBARS KW - animal models KW - diabetic complications KW - streptozotocin SP - 1082 EP - 1088 JF - Pharmaceutical biology JO - Pharm Biol VL - 55 IS - 1 N2 - CONTEXT: Syzygium cumini (L.) Skeels (Myrtaceae) is a medicinal plant widely used in folk medicine for the treatment of diabetes mellitus (DM). However, studies on the use of this plant and of nanoparticle formulations against DM-related fungal infections are scarce. OBJECTIVE: To evaluate the effect of the treatments with aqueous seed extract of S. cumini (ASc) and ASc-loaded polymeric nanoparticles (NPASc) on biochemical parameters in Candida albicans-infected diabetic rats. MATERIALS AND METHODS: Male Wistar rats were divided into eight groups: Control, DM, C. albicans, C. albicans + ASc, C. albicans + NPASc, DM + C. albicans, DM + C. albicans + ASc and DM + C. albicans + NPASc. Rats were daily treated with ASc or NPASc (100 mg/kg) for 21 days. Biochemical parameters in serum and urine, advanced oxidation protein product (AOPP) and TBARS levels in the serum, kidney, liver and pancreas and N-acetyl-β-d-glucosaminidase (NAG) activities in kidney and urine were evaluated. RESULTS: Biochemical and oxidative stress parameters increased in rats with DM and/or candidiasis. NPASc was more effective than ASc in decreasing glucose (56%), cholesterol (33%) and creatinine (51%) levels; serum (16%) and pancreatic (46%) AOPP and renal (48%) TBARS levels when compared with DM + C. albicans group. In C. albicans group, both treatments decreased NAG activity but did not decrease creatinine levels. CONCLUSIONS: These data suggest that the use of nanotechnology is able to improve plant extract properties such as antioxidant activity that may be useful in diabetes-related complications. SN - 1744-5116 UR - https://www.unboundmedicine.com/medline/citation/28193098/Nanoparticle_formulation_increases_Syzygium_cumini_antioxidant_activity_in_Candida_albicans_infected_diabetic_rats_ L2 - https://www.tandfonline.com/doi/full/10.1080/13880209.2017.1283338 DB - PRIME DP - Unbound Medicine ER -